Skip to content

Psilocybin: all studies

Page 65 of 439: studies 641 to 650 of 4,389, newest first. Back to the psilocybin overview

Research

Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.

Nature Neuroscience June 1, 2025 Sophie A. Rogers, Elizabeth A. Heller, Gregory Corder 11 citations

The psychedelic drug psilocybin demonstrates rapid and long-lasting efficacy across neuropsychiatric disorders that are characterized by behavioral inflexibility. However, its impact on the neural activity underlying sustained changes in behavioral flexibility has not been characterized. To test whether psilocybin enhances behavioral flexibility by altering activity in cortical neural...

DOI: 10.1038/s41593-025-01964-9 (opens in new tab) Full text (opens in new tab) Psychedelics Fear-response Brain-plasticity Behavioral-science

Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin

bioRxiv (Cold Spring Harbor Laboratory) May 30, 2025 Pavel Osten, K Sunny Joseph, Jane Collins et al. preprint

Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants that require weeks to take effect. Here, we conducted whole-brain screening in mice to compare drug-evoked c-fos expression—acting as a marker of brain activity leading to protein synthesis-dependent forms of plasticity—following treatment with...

Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population

medRxiv May 29, 2025 Paul B. Fitzgerald, Sara Webb, Nigel Christopher Denning et al. 2 citations preprint

Abstract Objective Despite many decades of experimental studies and clinical trials involving a variety of psychedelic agents, we still lack a comprehensive understanding of the effects of these substances on psychological experiences. As such, we designed and conducted a study to comprehensively characterise the effects of both psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) on a range...

Patients’ Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment

Journal of Psychoactive Drugs May 29, 2025 Araam Abboud, Kyle Hua, Hannah Redding et al. 1 citation

This study examined patient perspectives on psilocybin therapy, specifically their acceptance and views on the therapeutic benefits of both hallucinogenic and non-hallucinogenic forms. A cross-sectional survey was conducted among psychiatric patients aged 18-65 at a community mental health center, assessing their attitudes, knowledge, and acceptance of psilocybin therapy. In total, 62.4% of the...

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

Brain Sciences May 26, 2025 Charles Palmer, Ally T Ferber, Brian D Greenwald 4 citations

Background: This narrative review explores psilocybin’s potential use as a therapeutic agent in patients with traumatic brain injury (TBI). Methods: We engaged in a search of PubMed, ScienceDirect, and Cochrane’s databases for information on the effects of psilocybin. We also reviewed articles where psilocybin was used in patients with TBI. Articles from 2000–2025 were included. Results: A...

DOI: 10.3390/brainsci15060572 (opens in new tab) Neurogenesis Neuroplasticity Medical psilocybin Traumatic brain injury +12

Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats.

Scientific Reports May 26, 2025 Zitong Wang, Brett Robbins, Ryan Zhuang et al. 4 citations

Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant trials, approximately one-third of MDD patients remain symptomatic, progressing to treatment-resistant depression (TRD). This persistence possibly is due to the multifaceted etiology of TRD, encompassing biological, psychological, and environmental...

DOI: 10.1038/s41598-025-03383-z (opens in new tab) Full text (opens in new tab) Neuroscience research Depression treatment Psychedelics Mental health therapy +1

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

Journal of Eating Disorders May 26, 2025 Julie Trim, Samantha Shao, Nadav Liam Modlin et al. 14 citations

PT may hold promise not only in the treatment of eating disorders but also trauma-related disorders, including PTSD and dissociative amnesia. Potential mechanisms of psilocybin's facilitation of remembering and processing traumatic material is reviewed.

DOI: 10.1186/s40337-025-01274-2 (opens in new tab) Psilocybin Anorexia nervosa Psychotherapist Hallucinogen

Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice

The International Journal of Neuropsychopharmacology May 25, 2025 Ines Erkizia-Santamaría, Nerea Martínez-Álvarez, Leyre Salinas-Novoa et al. 7 citations

Abstract Background The psychedelic psilocybin has been posited as efficacious for the treatment of depression. However, the potential link between the intensity of acute psychedelic effects and long-term therapeutic outcomes remains undiscovered. Moreover, the impact of classical antidepressant drugs that modulate serotonergic activity on psilocybin’s effects is a clinically relevant concern....

[Psilocybin in the setting of treatment-resistant unipolar depression: A case report].

L'Encephale May 23, 2025 Maroussia Dumenil, Gabriel Cordova, Wissam El-Hage 1 citation

Current antidepressants have shown certain limitations in the treatment of unipolar depression. Their long onset of action, interactions, and side effects are obstacles to achieving lasting remission of this prevalent, often chronic or recurrent, pathology. Faced with this clinical necessity, research efforts have intensified in recent years around psychedelic drugs, with a particular focus on...

Psilocybe cubensis: potencial neuropsicofarmacéutico de la psilocibina y psilocina

Tecnología en Marcha May 20, 2025 Frank Barrientos-Alfaro, Valeria Herrera-Rojas, Michelle Montero-Quesada et al.

Los hongos juegan un papel clave en el mantenimiento de la vida en la tierra, ya que desempeñan múltiples funciones a nivel ecológico. Adicionalmente, son productores de diversos metabolitos secundarios, entre estos, los alcaloides, los cuales en ciertos casos pueden proveer propiedades alucinógenas. Psilocybe cubensis es una especie común de hongos alucinógenos conocida como “hongos mágicos”....

DOI: 10.18845/tm.v37i9.7618 (opens in new tab) Full text (opens in new tab) Alcaloides psicoactivos Hongos Potencial biomédico Fármaco alucinógeno